<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891357</url>
  </required_header>
  <id_info>
    <org_study_id>WSG-AM07 (Neo-PREDICT-HER2)</org_study_id>
    <secondary_id>2012-003679-21</secondary_id>
    <nct_id>NCT01891357</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer</brief_title>
  <official_title>A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response&#xD;
      evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast&#xD;
      cancer. The only treatment arm consists of Paclitaxel 80 mg/m2 weekly for 12 weeks with&#xD;
      lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trastuzumab (T)-containing neoadjuvant chemotherapy has been reported to increase the&#xD;
      probability of pathological complete response (pCR) in HER2 positive disease up to 67 %.&#xD;
      Large trials revealed pCR rates (no remaining invasive and in situ components) of about 30-40&#xD;
      %, if anthracyclines/taxane based polychemotherapy was applied or about 40-45 % if no&#xD;
      invasive tumor in the breast and lymph nodes was used as a pCR definition.&#xD;
&#xD;
      Nevertheless, resistance to trastuzumab remains one of the most important challenges in&#xD;
      adjuvant and metastatic breast cancer therapy causing poor prognosis with an increased&#xD;
      incidence of cerebral metastasis and limited therapeutic options after disease progression6.&#xD;
      An improvement shows the combination of trastuzumab and lapatinib, which has been reported to&#xD;
      have increased efficacy in in-vitro and in metastatic setting in patients who were mostly&#xD;
      resistant to both therapies in the previous course of disease. Recent data from the&#xD;
      neoadjuvant setting (neoALTTO) - on a paclitaxel backbone - showed a significantly higher pCR&#xD;
      rate after L + T than with either compound separately (47 % vs. 20 % and 27.6 %&#xD;
      respectively). Several trials are planned to evaluate the combination of both therapies in&#xD;
      the adjuvant and neoadjuvant setting.&#xD;
&#xD;
      Clinical response measured by sequential evaluation of different proliferation markers (such&#xD;
      as Ki-67) following a course of neoadjuvant chemotherapy has been demonstrated to correlate&#xD;
      significantly with an increased risk of relapse in patients not achieving pathological&#xD;
      complete response. It is therefore clinically relevant to evaluate such proliferation tools&#xD;
      for early prediction of combination therapy efficacy (chemotherapy and HER2 targeted&#xD;
      therapy). So far, it remains unclear which method of proliferation measurement is the optimal&#xD;
      marker for response evaluation regarding a combined chemo-immunotherapy. However, measurement&#xD;
      of proliferation and apoptosis genes as well as assessment of changes in Phosphatidylinositol&#xD;
      3-kinases (PI3K), Protein Kinase B (AKT), Insulin-like Growth Factor (IGF) and stem cell&#xD;
      signalling after a short course of therapy could provide a unique signature for a dynamic&#xD;
      response evaluation.&#xD;
&#xD;
      The planned trial will validate predictive markers and a dynamic model based on the&#xD;
      sequential evaluation of different proliferation and apoptosis markers. Furthermore it will&#xD;
      assess the pCR-rate after 12 weeks of therapy. The aim of the study is to define a predictive&#xD;
      marker for the response evaluation of a combined chemo-immunotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination due to significant lack of relevant patient data for evaluation of&#xD;
    objectives.&#xD;
  </why_stopped>
  <start_date type="Actual">September 30, 2013</start_date>
  <completion_date type="Actual">November 16, 2016</completion_date>
  <primary_completion_date type="Actual">November 16, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>Average of 16 weeks</time_frame>
    <description>pCR was defined at the time of surgery and measured by size of residual tumor, proportion of vital cells within invasive carcinoma, number of positive lymph nodes (ypN) and size of the largest lymph node metastasis and ductal carcinoma in situ (ypT). pCR is defined as ypT0/is, ypN0. Further exploratory pCR definitions were ypT0, ypN0 (total pCR) and ypT0/is (near pCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5-year survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5-year survival</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proliferation and Apoptosis Genes</measure>
    <time_frame>One week before and after three weeks of treatment</time_frame>
    <description>Proliferation Ki-67, Aurora A Kinase (STK15), survivin, Myb-related protein B (MYBL2),Cyclin B1 and apoptosis genes Bcl2, Epidermal Growth Factor-like 2 (SCUBE2), cleaved caspase C3 will be assessed in the samples from diagnostic and sequential biopsy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Carcinoma, Ductal, Breast</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy before and after three weeks of study treatment</intervention_name>
    <description>Core biopsies for histological analyses, to be analysed by the central pathology</description>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients, age at diagnosis 18 - 75 years&#xD;
&#xD;
          2. Histological confirmed unilateral primary invasive carcinoma of the breast&#xD;
&#xD;
          3. Clinical Stage Tumor 1 (cT1) (&gt; 1 cm) - Clinical Stage Tumor 4 (cT4) (if operable,&#xD;
             inflammatory breast cancer is excluded)&#xD;
&#xD;
          4. HER2 over-expressing tumor confirmed by: 3+ by Immuno-histochemistry (IHC) and/or&#xD;
             HER2/neu gene amplification by fluorescence, chromogenic or silver in-situ&#xD;
             hybridization [Fluorescent In-Situ Hybridization (FISH), Chromogenic In-Situ&#xD;
             Hybridization (CISH) or Silver In-Situ Hybridization (SISH); &gt; 6 HER2 gene copies per&#xD;
             nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals)&#xD;
             of ≥ 2.0]&#xD;
&#xD;
          5. Clinically node positive disease or node negative disease&#xD;
&#xD;
          6. No clinical evidence for distant metastasis (cM0) after conventional staging&#xD;
&#xD;
          7. Performance Status Eastern Cooperative Oncology Group (ECOG) ≤ 1 or Karnofsky Index&#xD;
             (KI) ≥ 80%&#xD;
&#xD;
          8. Baseline Left Ventricular Ejection Fraction (LVEF) &gt; 50% measured by echocardiography&#xD;
&#xD;
          9. Negative pregnancy test (urine or serum) within 7 days prior to start of induction&#xD;
             treatment in premenopausal patients&#xD;
&#xD;
         10. The patient must be accessible for treatment and follow-up&#xD;
&#xD;
         11. Written informed consent including a written informed consent for shipping of tumor&#xD;
             block for central pathology review and evaluation prior to the start of any study&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to the compounds or incorporated substances&#xD;
&#xD;
          2. Known polyneuropathy grade ≥ 2&#xD;
&#xD;
          3. Have acute or currently active or requiring anti-viral therapy hepatic or biliary&#xD;
             disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones,&#xD;
             stable chronic liver disease per investigator assessment).&#xD;
&#xD;
          4. Prior malignancy with a disease-free survival of &lt; 10 years, except curatively treated&#xD;
             basalioma of the skin, pTis of the cervix uteri&#xD;
&#xD;
          5. Prior or concurrent treatment with cytotoxic agents for any reason after consultation&#xD;
             with the sponsor&#xD;
&#xD;
          6. Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry&#xD;
&#xD;
          7. Male breast cancer&#xD;
&#xD;
          8. Concurrent pregnancy; patients of childbearing potential must implement a highly&#xD;
             effective (less than 1% failure rate) non-hormonal contraceptive measures during the&#xD;
             study treatment&#xD;
&#xD;
          9. Breast feeding women&#xD;
&#xD;
         10. Sequential breast cancer&#xD;
&#xD;
         11. Lack of patient compliance&#xD;
&#xD;
         12. Inadequate organ function including:&#xD;
&#xD;
               -  Leucocytes &lt; 3.5 x 109/l&#xD;
&#xD;
               -  Platelets &lt; 100 x 109/l&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) &lt; 1.5 x 109/l&#xD;
&#xD;
               -  Hemoglobin &lt; 9 g/dl&#xD;
&#xD;
               -  Serum Creatinine &gt; 1.5 mg/dl&#xD;
&#xD;
               -  Serum Bilirubin &gt; 1.1 mg/dl&#xD;
&#xD;
               -  Alkaline phosphatase &gt; 2.5 x Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Aspartate Transaminase (ASAT) and/or Alanine Transaminase (ALAT) &gt; 2.5 ULN&#xD;
&#xD;
               -  Albumin &lt; 2.5 g/dl&#xD;
&#xD;
         13. Uncompensated cardiac function&#xD;
&#xD;
         14. Malabsorption syndrome, disease significantly affecting gastrointestinal function&#xD;
&#xD;
         15. Concomitant use of Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Warm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Köln Holweide</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <state>Baden-Württemberg</state>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst</name>
      <address>
        <city>Frankfurt (Main)</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken</name>
      <address>
        <city>Georgsmarienhütte</city>
        <state>Niedersachsen</state>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Westfalen GmbH - Knappschaftskrankenhaus</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Krankenhaus, Senologie</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Barbara-KIinik</name>
      <address>
        <city>Hamm</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Köln Holweide, Brustzentrum</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für gynäkologische Onkologie am Brustzentrum City</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2013</study_first_posted>
  <results_first_submitted>August 12, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unilateral primary invasive carcinoma of the breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients should only have been registered for the study, if final results of screening evaluations were available and all inclusion/exclusion criteria met. This was not true for 3 patients.&#xD;
Patients should not have been registered due to distant metastasis. These patients were classified as screening failures and withdrawn from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paclitaxel + Lapatinib + Trastuzumab</title>
          <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT: Intent-to-treat population of all randomized patients without screening failures, comprising 61 patients (3 screening failures).</population>
      <group_list>
        <group group_id="B1">
          <title>Paclitaxel + Lapatinib + Trastuzumab</title>
          <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Demographics of All Registered Patients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathological Complete Response (pCR)</title>
        <description>pCR was defined at the time of surgery and measured by size of residual tumor, proportion of vital cells within invasive carcinoma, number of positive lymph nodes (ypN) and size of the largest lymph node metastasis and ductal carcinoma in situ (ypT). pCR is defined as ypT0/is, ypN0. Further exploratory pCR definitions were ypT0, ypN0 (total pCR) and ypT0/is (near pCR).</description>
        <time_frame>Average of 16 weeks</time_frame>
        <population>Measurement of pCR: at time of surgery, measured by size of residual tumor, proportion of vital cells per invasive carcinoma, number of positive lymph nodes (ypN), size of largest lymph node metastasis, ductal carcinoma in situ (ypT). Definition of pCR: ypT0/is, ypN0. Exploratory pCR definition: ypT0, ypN0 (total pCR), ypT0/is (near pCR).</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel + Lapatinib + Trastuzumab</title>
            <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Response (pCR)</title>
          <description>pCR was defined at the time of surgery and measured by size of residual tumor, proportion of vital cells within invasive carcinoma, number of positive lymph nodes (ypN) and size of the largest lymph node metastasis and ductal carcinoma in situ (ypT). pCR is defined as ypT0/is, ypN0. Further exploratory pCR definitions were ypT0, ypN0 (total pCR) and ypT0/is (near pCR).</description>
          <population>Measurement of pCR: at time of surgery, measured by size of residual tumor, proportion of vital cells per invasive carcinoma, number of positive lymph nodes (ypN), size of largest lymph node metastasis, ductal carcinoma in situ (ypT). Definition of pCR: ypT0/is, ypN0. Exploratory pCR definition: ypT0, ypN0 (total pCR), ypT0/is (near pCR).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ypT0, ypN0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ypT0/is</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ypT0/is, ypN0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival (EFS)</title>
        <time_frame>5-year survival</time_frame>
        <population>Data were not collected and the outcome cannot be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel + Lapatinib + Trastuzumab</title>
            <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival (EFS)</title>
          <population>Data were not collected and the outcome cannot be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>5-year survival</time_frame>
        <population>Data were not collected and the outcome cannot be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel + Lapatinib + Trastuzumab</title>
            <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <population>Data were not collected and the outcome cannot be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proliferation and Apoptosis Genes</title>
        <description>Proliferation Ki-67, Aurora A Kinase (STK15), survivin, Myb-related protein B (MYBL2),Cyclin B1 and apoptosis genes Bcl2, Epidermal Growth Factor-like 2 (SCUBE2), cleaved caspase C3 will be assessed in the samples from diagnostic and sequential biopsy.</description>
        <time_frame>One week before and after three weeks of treatment</time_frame>
        <population>Data were not collected and the outcome cannot be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel + Lapatinib + Trastuzumab</title>
            <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Proliferation and Apoptosis Genes</title>
          <description>Proliferation Ki-67, Aurora A Kinase (STK15), survivin, Myb-related protein B (MYBL2),Cyclin B1 and apoptosis genes Bcl2, Epidermal Growth Factor-like 2 (SCUBE2), cleaved caspase C3 will be assessed in the samples from diagnostic and sequential biopsy.</description>
          <population>Data were not collected and the outcome cannot be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE collection from signature of ICF until end of study per patient, up to 3 years.</time_frame>
      <desc>Safety population for analysis of toxicities, comprised of 61 patients who were allocated to intervention and received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paclitaxel + Lapatinib + Trastuzumab</title>
          <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment&#xD;
Biopsy before and after three weeks of study treatment: Core biopsies for histological analyses, to be analysed by the central pathology&#xD;
paclitaxel&#xD;
lapatinib&#xD;
trastuzumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE version 4.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Leukopenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <description>Ophthalmic herpes simplex</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Cholecystitis</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Decreased appetite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <description>diarrhoea</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <description>septic shock</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokaleamia</sub_title>
                <description>hypokaleamia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>suicide</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <description>Anxiety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Dehydration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Urinary tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>Urosepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>impaired healing</sub_title>
                <description>impaired healing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <description>Mucosal Inflammation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <description>Subcutaneous abscess</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <description>Device related thrombosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI-CTCAE version 4.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <description>Blood and lymphatic system disorders</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <description>Ear and labyrinth disorders</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <description>Eye disorders</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Gastrointestinal disorders</description>
                <counts group_id="E1" events="133" subjects_affected="59" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <description>Hepatobiliary disorders</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <description>Immune system disorders</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Infections and infestations</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>Injury, poisoning and procedural complications</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Investigations</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nMetabolism and nutrition disordersutrition disorders</sub_title>
                <description>Metabolism and nutrition disorders</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>Musculoskeletal and connective tissue disorders</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Nervous system disorders</description>
                <counts group_id="E1" events="66" subjects_affected="59" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>Psychiatric disorders</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Renal and urinary disorders</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <description>Reproductive system and breast disorders</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Respiratory, thoracic and mediastinal disorders</description>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>Skin and subcutaneous tissue disorders</description>
                <counts group_id="E1" events="93" subjects_affected="59" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <description>Vascular disorders</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only a limited number of core biopsies was available evaluation of dynamic biological changes.&#xD;
Very slow patient recruitment. Negative study results from ALTTO study did no longer justify further conduct.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anja Braschoss, Consultant Clinical Research and Medical Writing</name_or_title>
      <organization>on behalf of Westdeutsche Studiengruppe GmbH</organization>
      <phone>0049-176-82119153</phone>
      <email>anja.braschoss@wsg-online.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

